New vaccine to treat brain tumor passes first tests

The results of the first clinical trials of the new anti-glomeruloblast vaccine have shown its great effectiveness in curbing tumor growth.

Scientists at Thomas Jefferson University have tested IGV-001, a vaccine against brain cancer in the United States, in 33 patients with thyroid cancer.

According to the researchers, "the vaccine has slowed the growth of the tumor and prolonged the patient's life by several months," and it is important not to detect side effects.

According to a statement released by the researchers, the vaccine relies on cancer cells taken from a patient during a surgical operation to remove the tumor. These cells are treated with special substances and then reinjected into the body.

Read more

The researchers used two different doses of these cells in the first-phase tests and found that when the highest dose was used, tumor growth stopped and the patient lived 21.9 months. Patients who received traditional treatment lived 14.6 months. The researchers said they observed the condition of some patients after using the vaccine for 39 months.

The second phase of clinical trials of this effective vaccine is expected to begin in the final months of this year.

Source: Forum Medicom